177
Views
24
CrossRef citations to date
0
Altmetric
Research Report

Cost–effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden

, , , , &
Pages 601-615 | Published online: 09 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Charles Mahan & Alex C. Spyropoulos. (2012) Improving prevention and treatment of venous thromboembolism: clinical trial results. Journal of Medical Economics 15:4, pages 611-622.
Read now

Articles from other publishers (23)

Sajesh K. Veettil, Jordi Harris, M. Sakil Syeed, Ammarin Thakkinstian, Usa Chaikledkaew, Daniel M. Witt & Nathorn Chaiyakunapruk. (2022) Incremental net monetary benefit of direct oral anticoagulants for the prevention of venous thromboembolism after total knee or hip replacement: A systematic review and meta-analysis. Thrombosis Research 216, pages 74-83.
Crossref
. (2022) Recommendations from the ICM-VTE: General. Journal of Bone and Joint Surgery 104:Suppl 1, pages 4-162.
Crossref
Joshua Xu, David Chang, Juanita Chui, Jacob Cao & Jonathan Negus. (2022) The efficacy and cost-effectiveness of enoxaparin versus rivaroxaban in the prevention of venous thromboembolism following total hip or knee arthroplasty: A meta-analysis. Journal of Orthopaedics 30, pages 1-6.
Crossref
Charlie J. Nederpelt, Quinten Bijman, Pieta Krijnen & Inger B. Schipper. (2022) Equivalence of DOACS and LMWH for thromboprophylaxis after hip fracture surgery: Systematic review and meta-analysis. Injury 53:3, pages 1169-1176.
Crossref
Kaidireyahan Wumaier, Wenqian Li, Naifei Chen & Jiuwei Cui. (2021) Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis. Thrombosis Journal 19:1.
Crossref
Aziz Rezapour, Aghdas Souresrafil & Jalal Arabloo. (2021) Economic Evaluation of New Oral Anticoagulants in Prevention of Venous Thrombosis Following Joint Replacement Surgery: A Systematic Review. Clinical Therapeutics 43:5, pages e139-e156.
Crossref
Charlie J. Nederpelt, Kerry A. Breen, Majed W. el Hechi, Pieta Krijnen, Menno V. Huisman, Inger B. Schipper, Haytham M.A. Kaafarani & Martin G. Rosenthal. (2021) Direct Oral Anticoagulants Are a Potential Alternative to Low-Molecular-Weight Heparin for Thromboprophylaxis in Trauma Patients Sustaining Lower Extremity Fractures. Journal of Surgical Research 258, pages 324-331.
Crossref
Codie A. Primeau, Ishita Joshi, Bryn O. Zomar, Lyndsay E. Somerville, Holly T. Philpott, David D. McHugh, Brent A. Lanting, Edward M. Vasarhelyi & Jacquelyn D. Marsh. (2020) Cost-Effectiveness of Arthroplasty Management in Hip and Knee Osteoarthritis: a Quality Review of the Literature. Current Treatment Options in Rheumatology 6:3, pages 160-190.
Crossref
Asma Rashki Kemmak, Ali Abutorabi & Vahid Alipour. (2020) Economic Evaluation of Rivaroxaban Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Knee Replacement and Total Hip Replacement: A Systematic Review. Clinical Drug Investigation 40:8, pages 715-725.
Crossref
Dalia M. Dawoud, David Wonderling, Jessica Glen, Sedina Lewis, Xavier L. Griffin, Beverley J. Hunt, Gerard Stansby, Michael Reed, Nigel Rossiter, Jagjot Kaur Chahal, Carlos Sharpin & Peter Barry. (2018) Cost-Utility Analysis of Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip and Total Knee Replacement Surgeries in the English National Health Service. Frontiers in Pharmacology 9.
Crossref
Hai-Feng Huang, Shan-Shan Li, Xian-Teng Yang, Quan Xie & Xiao-Bin Tian. (2018) Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty. Medicine 97:48, pages e13465.
Crossref
George Gourzoulidis, Georgia Kourlaba, John Kakisis, Mitiadis Matsagkas, George Giannakoulas, Konstantinos I. Gourgoulianis, Theodoros Vassilakopoulos & Nikos Maniadakis. (2017) Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece. Clinical Drug Investigation 37:9, pages 833-844.
Crossref
James Brockbank & Sorrel Wolowacz. (2017) Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement: A Systematic Review. PharmacoEconomics 35:5, pages 517-535.
Crossref
Felipe de Santana Bosmak, Patrick Teller Gibim, Sandra Guimarães & Adriano Luiz Ammirati. (2017) Incidence of delirium in postoperative patients treated with total knee and hip arthroplasty. Revista da Associação Médica Brasileira 63:3, pages 248-251.
Crossref
Xiaoyu Yan, Xiaohua Gu, Zhenxing Xu, Houweng Lin & Bin Wu. (2016) Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China. Advances in Therapy 34:2, pages 466-480.
Crossref
Xiaoyu Yan, Xiaohua Gu, Lei Zhou, Houweng Lin & Bin Wu. (2016) Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China. Clinical Drug Investigation 36:12, pages 1001-1010.
Crossref
Sotiris Antoniou. (2015) Rivaroxaban for the treatment and prevention of thromboembolic disease. Journal of Pharmacy and Pharmacology 67:8, pages 1119-1132.
Crossref
Joseph F. Konopka, Andreas H. Gomoll, Thomas S. Thornhill, Jeffrey N. Katz & Elena Losina. (2015) The Cost-Effectiveness of Surgical Treatment of Medial Unicompartmental Knee Osteoarthritis in Younger Patients. Journal of Bone and Joint Surgery 97:10, pages 807-817.
Crossref
Sérgio Nuno Craveiro Barra, Luís Paiva, Rui Providência, Andreia Fernandes & António Leitão Marques. (2013) A Review on State-of-the-Art Data Regarding Safe Early Discharge Following Admission for Pulmonary Embolism: What Do We Know?. Clinical Cardiology 36:9, pages 507-515.
Crossref
Mario Lenza, Silvia de Barros Ferraz, Dan Carai Maia Viola, Reynaldo Jesus Garcia Filho, Miguel Cendoroglo Neto & Mario Ferretti. (2013) Epidemiology of total hip and knee replacement: a cross-sectional study. Einstein (São Paulo) 11:2, pages 197-202.
Crossref
M.A. Prieto-Díaz. (2013) Evidencias sobre el coste económico de los nuevos anticoagulantes. SEMERGEN - Medicina de Familia 39, pages 30-35.
Crossref
. (2012) Current World Literature. Current Opinion in Cardiology 27:5, pages 556-564.
Crossref
Charles E. Mahan, Matthew E. Borrego, Alex L. Woersching, Robert Federici, Ross Downey, Jay Tiongson, Mark C. Bieniarz, Brendan J. Cavanaugh & Alex C. Spyropoulos. (2017) Venous thromboembolism: Annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. Thrombosis and Haemostasis 108:08, pages 291-302.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.